Peterarthur
Eli Lilly has yet to publish the full results, which means the data has not been peer reviewed or independently verified, so experts have only been able to comment on the press release.
Alzheimer drugs: How donanemab compares to lecanemab...
Peterarthur
writing for the journal Science, Derek Lowe, who works in drug discovery, commented that "we are surely looking at the most optimistic take possible — we'll have to wait for filing with the FDA to see more."
Alzheimer drugs: How donanemab compares to lecanemab...
Peterarthur
Alzheimer's disease affects at least 55 million people worldwide.

The World Health Organization says Alzheimer's disease is the most common form of dementia — "dementia is the seventh leading cause of death and one of the major causes of disability and dependency among older people globally."

Dementia is one of the hardest conditions to treat.
Peterarthur
As with similar antibody-based therapies such as lecanemab, donanemab is not a cure for Alzheimer's.

Instead, they are antibodies that target different forms of amyloid-beta (Aβ) proteins that can clump together to form amyloid plaques in people's brains, resulting in their cognitive decline.
Peterarthur
Both drugs are given intravenously, but the doses are different — donanemab was given every four weeks and lecanemab every two weeks.

Both drugs were only tested on people with early stages of Alzheimer's.
Peterarthur
Three deaths in the donanemab trials
Both donanemab and lecanemab have a high-risk of side effects, wrote the journal Nature in a May 4 news article.

The side effects include "amyloid-related imaging abnormalities" — or ARIA — which include swelling or bleeding in the brain.
Peterarthur
Lecanemab's phase 3 results showed that 17% of participants had brain bleeds and 13% had brain swellings, which is less than donanemab. But Biogen and Eisai, the companies behind lecanemab, have also reported three deaths associated with the drug.
載入新的回覆